Clik here to view.
Angiotech posts positive results in MultiStem trial
Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) and partner Athersys (NASDAQ:ATHX) have released positive results from the Phase 1 clinical trial of MultiStem, an allogeneic-cell-therapy product,...
View ArticleClik here to view.
Angiotech releases updates results for Multistem
Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) and partner Athersys (NASDAQ:ATHX) released updated results from the Phase 1 clinical trial of MultiStem, the allogeneic cell therapy product,...
View ArticleClik here to view.
Angiotech provides follow-up Taxus trial data
Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) and its corporate partner, Boston Scientific (NYSE:BSX), have released three-year follow-up data from the Horizons AMI trial designed to determine the...
View ArticleClik here to view.
Angiotech defers interest payment; in talks to reduce debt
Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) will not make interest payments totalling about $9.7-million due today to holders of its subordinated notes as the company is in discussions with note...
View ArticleClik here to view.
Angiotech in recapitalization agreement
Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) has entered into a recapitalization support agreement with holders of about 73% of its 7.75% senior subordinated notes that would eliminate $250 million...
View ArticleClik here to view.
RBC cuts Angiotech price target
RBC Capital Markets has slashed its price target on Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) to 10 cents (U.S.) from 50 cents, while maintaining an “underperform speculative risk” rating in the...
View ArticleClik here to view.
Angiotech in supply pact with Hologic
Angiotech Pharmaceuticals (TSX;ANP;NASDAQ:ANPI) has entered into an initial three-year private label product supply agreement in the U.S. with Hologic (NASDAQ: HOLX) for soft tissue breast biopsy...
View ArticleClik here to view.
Angiotech coming off NASDAQ Jan. 13
Shares of Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) will be delisted from NASDAQ on Jan. 13 because the company failed to regain compliance with the exchange’s listing requirements within a...
View ArticleClik here to view.
Angiotech files for bankruptcy protection under CCAA
The board of Angiotech Pharmaceuticals (TSX:ANP) has authorized the company and certain subsidiaries to voluntarily file under the Companies’ Creditors Arrangement Act (CCAA) in order to continue...
View Article
